|
|
|
|
||
Re: Biomarin R&D day: massive patient-to-patient variability for Hemo AIt will be interesting to see what the FDA Advisory Board will recommend,which I guess will be after ASH. I am sure Biomarin will Lobby the FDA if the Advisory Board Rejects their submission. WHAT IS YOUR ASSESSMENT RE WHAT do you think will be the consensus of the doctors re their l recommendations to their patients ? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
136580 | Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A | spaddy | 5 | 11/17/2019 9:49:43 PM |